Currently, Nuvation Bio Inc [NUVB] is trading at $2.77, up 4.53%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The NUVB shares have gain 6.54% over the last week, with a monthly amount glided 2.97%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Nuvation Bio Inc [NYSE: NUVB] stock has seen the most recent analyst activity on March 27, 2024, when Jefferies upgraded its rating to a Buy and also boosted its price target to $10 from $1.40. Previously, BTIG Research upgraded its rating to Buy on March 26, 2024, and kept the price target unchanged to $5. On January 06, 2023, downgrade downgraded it’s rating to Hold and revised its price target to $2 on the stock. BTIG Research downgraded its rating to a Neutral. BMO Capital Markets downgraded its rating to a Market Perform and reduced its price target to $2.50 on August 02, 2022. H.C. Wainwright started tracking with a Buy rating for this stock on May 04, 2022, and assigned it a price target of $14.
This stock has fluctuated between a low of $1.52 and a high of $4.16 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. Nuvation Bio Inc [NYSE: NUVB] shares were valued at $2.77 at the most recent close of the market. An investor can expect a potential return of 152.71% based on the average NUVB price forecast.
Analyzing the NUVB fundamentals
Gross Profit Margin for this corporation currently stands at -0.33% with Operating Profit Margin at -55.42%, Pretax Profit Margin comes in at -219.41%, and Net Profit Margin reading is -219.41%. To continue investigating profitability, this company’s Return on Assets is posted at -0.93, Equity is -1.09 and Total Capital is -0.26. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.65 points at the first support level, and at 2.52 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.86, and for the 2nd resistance point, it is at 2.94.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Nuvation Bio Inc [NYSE:NUVB] is 9.57. Further, the Quick Ratio stands at 9.57, while the Cash Ratio is 0.51. Considering the valuation of this stock, the price to sales ratio is 432.90, the price to book ratio is 1.85.
Transactions by insiders
Recent insider trading involved Wang Junyuan Jerry, CEO, ANHEART THERAPEUTICS LTD., that happened on Nov 11 ’24 when 56361.0 shares were sold. Director, Mashal Robert completed a deal on Oct 08 ’24 to buy 100000.0 shares. Meanwhile, Director Cui Xiangmin bought 0.28 million shares on Jun 25 ’24.
